https://pharmadevicenews.com/novartis-lowered-a-major-inherited-heart-risk-marker-by-78-why-did-patients-not-benefit/ PharmaDeviceNews en 2026-11-08T16:52:26+00:00 Novartis lowered a major inherited heart-risk marker by 78%. Why did patients not benefit? American Heart Association, Amgen, Eli Lilly and Company, Ionis Pharmaceuticals, lepodisiran, Lp(a)HORIZON, Novartis, olpasiran, pelacarsen https://pharmadevicenews.com/wp-content/uploads/2026/05/Ribos-RBD1119-Phase-2-filing-puts-siRNA-antithrombotics-into-sharper-cardiovascular-focus-e1779979227353.webp https://pharmadevicenews.com/rybrevant-faspro-shrank-tumours-in-42-of-heavily-treated-head-and-neck-cancer-patients-can-phase-3-confirm-the-benefit/ PharmaDeviceNews en 2026-11-08T16:46:31+00:00 Rybrevant Faspro shrank tumours in 42% of heavily treated head and neck cancer patients. Can Phase 3 confirm the benefit? amivantamab, Halozyme Therapeutics, Janssen Biotech, Johnson & Johnson, OrigAMI-4, OrigAMI-5, RYBREVANT FASPRO, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/Natera-expands-Signatera-evidence-with-head-to-head-Merkel-cell-carcinoma-study-e1784720429133.webp https://pharmadevicenews.com/can-samsung-bioepis-challenge-keytruda-after-its-u-s-patent-cliff-begins-in-2028/ PharmaDeviceNews en 2026-11-07T15:32:42+00:00 Can Samsung Bioepis challenge Keytruda after its U.S. patent cliff begins in 2028? Formycon, FYB206, Keytruda, Keytruda Qlex, Merck & Co., pembrolizumab, Samsung Bioepis, Samsung Epis Holdings, SB27, Society for Immunotherapy of Cancer, Zydus Lifesciences https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-17-2026-09_15_56-AM-e1789616803290.webp https://pharmadevicenews.com/siemens-healthineers-carves-out-diagnostics-business-as-olyrian-after-q4-margin-falls-to-5-4/ PharmaDeviceNews en 2026-11-07T15:25:18+00:00 Siemens Healthineers carves out diagnostics business as Olyrian after Q4 margin falls to 5.4% Olyrian Diagnostics, Siemens AG, Siemens Healthineers https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Diagnostics-generic.webp https://pharmadevicenews.com/johnson-johnson-tests-rybrevant-beyond-nsclc-as-origami-5-phase-3-trial-advances/ PharmaDeviceNews en 2026-11-07T15:17:14+00:00 Johnson & Johnson tests Rybrevant beyond NSCLC as OrigAMI-5 Phase 3 trial advances amivantamab, Janssen Biotech, Johnson & Johnson, OrigAMI-4, OrigAMI-5, RYBREVANT FASPRO, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/01/ovarian-cancer-research-and-drug-development.webp https://pharmadevicenews.com/immunocore-saw-70-of-first-line-patients-alive-at-two-years-can-two-t-cell-engagers-really-beat-kimmtrak-alone/ PharmaDeviceNews en 2026-11-07T14:46:57+00:00 Immunocore saw 70% of first-line patients alive at two years. Can two T-cell engagers really beat KIMMTRAK alone? Brenetafusp, DUET-UVEAL, gp100, IMC-F106C-101, Immunocore Holdings plc, KIMMTRAK, PRAME, Society for Immunotherapy of Cancer, tebentafusp https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-research-lab.webp https://pharmadevicenews.com/agenus-botbal-shows-long-term-survival-in-refractory-mss-colorectal-cancer/ PharmaDeviceNews en 2026-11-07T14:39:03+00:00 Agenus BOT+BAL shows long-term survival in refractory MSS colorectal cancer Agenus, balstilimab, BOT+BAL, botensilimab, C-800-01, ROBBIN https://pharmadevicenews.com/wp-content/uploads/2026/06/Genentechs-Tecentriq-review-raises-hopes-for-a-new-adjuvant-colon-cancer-standard-e1781193946367.webp https://pharmadevicenews.com/bristol-myers-squibb-camzyos-franchise-reaches-1-15bn-as-pediatric-evidence-expands/ PharmaDeviceNews en 2026-11-07T14:35:38+00:00 Bristol Myers Squibb Camzyos franchise reaches $1.15bn as pediatric evidence expands Bristol Myers Squibb, Camzyos, Cytokinetics, Mavacamten, Myqorzo, SCOUT-HCM, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/Cardiologist-review-e1785437553884.webp https://pharmadevicenews.com/metavias-tiny-phase-1-obesity-study-just-posted-13-5-weight-loss-and-a-68-liver-fat-reduction-how-much-can-investors-trust-yet/ PharmaDeviceNews en 2026-11-07T14:20:16+00:00 MetaVia’s tiny Phase 1 obesity study just posted 13.5% weight loss and a 68% liver-fat reduction. How much can investors trust yet? DA-1726, MetaVia, Precision Liver Symposium https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Clinical-Trials.webp https://pharmadevicenews.com/onkos-can-put-its-antibacterial-coating-on-more-implants-the-fda-claim-stops-well-short-of-preventing-infection/ PharmaDeviceNews en 2026-11-07T14:16:54+00:00 Onkos can put its antibacterial coating on more implants. The FDA claim stops well short of preventing infection ELEOS Limb Salvage System, NanoCept, NanoCept Innovation Center, Onkos Surgical, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Medical-Devices.webp https://pharmadevicenews.com/can-moderna-sustain-its-comeback-beyond-covid-vaccines-and-intismeran/ PharmaDeviceNews en 2026-11-07T14:12:43+00:00 Can Moderna sustain its comeback beyond COVID vaccines and intismeran? intismeran autogene, Merck & Co., MFLUSIVA, mNEXSPIKE, Moderna, mRESVIA, Spikevax https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-19-2026-07_56_50-PM-e1789828044512.webp https://pharmadevicenews.com/immunocore-reports-70-two-year-survival-with-dual-t-cell-engager-combination-in-uveal-melanoma/ PharmaDeviceNews en 2026-11-07T13:42:16+00:00 Immunocore reports 70% two-year survival with dual T-cell engager combination in uveal melanoma Brenetafusp, DUET-UVEAL, Immunocore Holdings, KIMMTRAK, Society for Immunotherapy of Cancer, tebentafusp https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/what-the-zolgensma-tumour-reports-mean-for-novartis-and-aav-gene-therapy-safety/ PharmaDeviceNews en 2026-11-07T13:29:29+00:00 What the Zolgensma tumour reports mean for Novartis and AAV gene therapy safety GLI1, Itvisma, Novartis AG, onasemnogene abeparvovec, U.S. Food and Drug Administration, Zolgensma https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/can-branded-glp-1-medicines-replace-compounded-weight-loss-drugs-in-hims-hers-growth-strategy/ PharmaDeviceNews en 2026-11-07T05:06:10+00:00 Can branded GLP-1 medicines replace compounded weight-loss drugs in Hims & Hers growth strategy? Eli Lilly and Company, Foundayo, Hims & Hers Health, LillyDirect, Novo Nordisk, orforglipron, Ozempic, tirzepatide, Wegovy, Zepbound https://pharmadevicenews.com/wp-content/uploads/2026/11/Eli-Lilly-expands-Foundayo-and-Zepbound-distribution-through-Hims-Hers-e1793975990967.webp https://pharmadevicenews.com/bucked-up-rolls-out-ten-winter-pre-workouts-but-what-does-400-mg-caffeine-mean/ PharmaDeviceNews en 2026-11-07T04:08:13+00:00 Bucked Up rolls out ten winter pre-workouts, but what does 400 mg caffeine mean? BAMF, Bucked Up, Erin Bettner, Frosted Cranberry, LFG Burn, Mother Bucker, SPINS, Winter Razz, Woke AF https://pharmadevicenews.com/wp-content/uploads/2026/11/Bucked-Up-launches-Winter-Razz-and-Frosted-Cranberry-pre-workout-flavours-scaled-e1794024454723.webp https://pharmadevicenews.com/baycare-fits-proton-therapy-into-a-conventional-radiation-vault-but-can-the-model-scale/ PharmaDeviceNews en 2026-11-07T04:02:39+00:00 BayCare fits proton therapy into a conventional radiation vault, but can the model scale? BayCare Cancer Institute, BayCare Health System, BayCare Proton Center, Florida, John Greskovich, Leo Cancer Care, Marie, Mevion Medical Systems, MEVION S250-FIT, RaySearch Laboratories, RayStation, St. Joseph's Hospital, Stephen Towe, Tampa, Tina Yu https://pharmadevicenews.com/wp-content/uploads/2026/11/BayCare-begins-Mevion-S250-FIT-proton-therapy-at-33-million-Tampa-centre-e1793982504587.webp https://pharmadevicenews.com/sky-0515-showed-a-1-59-point-huntingtons-disease-benefit-but-can-skyhawk-confirm-it/ PharmaDeviceNews en 2026-11-07T03:54:35+00:00 SKY-0515 showed a 1.59-point Huntington’s disease benefit, but can Skyhawk confirm it? Beth Israel Deaconess Medical Center, Bill Haney, CenExel Movement Disorder Center, Enroll-HD, FALCON-HD, Samuel Frank, SKY-0515, Skyhawk Therapeutics, SKYSTAR https://pharmadevicenews.com/wp-content/uploads/2026/07/Huntingtons-disease-drug-research-e1783863352980.webp https://pharmadevicenews.com/sarepta-cuts-its-operating-loss-to-9m-but-can-new-rna-drugs-offset-elevidys-decline/ PharmaDeviceNews en 2026-11-07T03:46:54+00:00 Sarepta cuts its operating loss to $9m, but can new RNA drugs offset Elevidys’ decline? Amondys 45, Arrowhead Pharmaceuticals, Catalent, delandistrogene moxeparvovec, ELEVIDYS, Exondys 51, Michael Severino, Roche, Sarepta Therapeutics, SRP-1001, SRP-1003, United States Food and Drug Administration, Vyondys 53 https://pharmadevicenews.com/wp-content/uploads/2026/08/Muscular-dystrophy-study-e1787597771792.webp https://pharmadevicenews.com/novo-nordisk-buys-ginkgo-bioworks-autonomous-lab-can-robotics-rescue-its-shrinking-revenue/ PharmaDeviceNews en 2026-11-07T03:42:39+00:00 Novo Nordisk buys Ginkgo Bioworks’ autonomous lab. Can robotics rescue its shrinking revenue? AbbVie, ADME-One, Advanced Research Projects Agency for Health, argenx, Ginkgo Bioworks, Jason Kelly, Lundbeck, National Science Foundation, Nebula, Novo Nordisk, Pacific Northwest National Laboratory, Takeda Pharmaceutical Company https://pharmadevicenews.com/wp-content/uploads/2026/08/AI-is-moving-from-answering-questions-to-running-laboratory-experiments.-Drug-discovery-may-never-look-the-same-e1788078274424.webp https://pharmadevicenews.com/abcelleras-abcl635-cut-hot-flashes-by-83-can-the-biotech-turn-phase-2-success-into-a-viable-drug/ PharmaDeviceNews en 2026-11-07T03:36:33+00:00 AbCellera’s ABCL635 cut hot flashes by 83%. Can the biotech turn Phase 2 success into a viable drug? AbCellera Biologics, ABCL386, ABCL575, ABCL635, ABCL688, Carl Hansen, Jazz Pharmaceuticals, The Menopause Society, UBS, United States Food and Drug Administration, Vertex Pharmaceuticals https://pharmadevicenews.com/wp-content/uploads/2026/08/AbCellera-ABCL635-trial-tests-long-acting-NK3-antibody-for-vasomotor-symptoms-e1786248781925.webp